Khiron Life Sciences Corp.

OTC: KHRNF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCReports USD

#624 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

——

FH —DQ —GM —SS 36

v0.1 · 5/100 weight · pillars only

↑ 3-yr revenue growth, revenue growth (YoY) · ↓ market scale, growth stability

Methodology →

Revenue TTM

$12.7M

Rev growth YoY (TTM)

+36.8%

Net income (FY)

-$26.4M

Employees

310

Market cap

$2.3k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$10.2M12.8M CAD2021

Net income-$26.4M-33.1M CAD2021

Operating income-$15.8M-19.8M CAD2021

Total assets$33.3M42.3M CAD2021

Liabilities$7.1M8.9M CAD2021

Equity$26.3M33.3M CAD2021

Revenue trend

FY2017 – FY2021 · USD

FY17

$688.2k

FY18

$7.2M

FY19

$6.0M

FY20

$10.2M

FY21

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Khiron Life Sciences Corp. booked $10.2M in FY2021 revenue, growing 71% year over year — faster than most Healthcare companies we track, at a -258.9% net margin.

Peers · Healthcare

Longport, Inc.——Regnum Corp.——OncoVista Innovative Therapies, Inc.——Global Hemp Group Inc.——

Key facts

CEOAlvaro Francisco Torres

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: KHRNF

Employees310

IPO date2021-01-08

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.